help button home button Endocrine Society Molecular Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on August 23, 2007
Molecular Endocrinology, doi:10.1210/me.2007-0323
A more recent version of this article appeared on December 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
21/12/3050    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, Y.
Right arrow Articles by Billiard, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, Y.
Right arrow Articles by Billiard, J.

Submitted on June 26, 2007
Accepted on August 15, 2007

Homo-dimerization of Ror2 Tyrosine Kinase Receptor Induces 14–3-3{beta} Phosphorylation and Promotes Osteoblast Differentiation and Bone Formation

Yan Liu, John F. Ross, Peter V.N. Bodine, and Julia Billiard*

Women's Health & Musculoskeletal Biology, Wyeth Research, Collegeville, PA and Biological Technologies, Wyeth Research, Cambridge, MA

* To whom correspondence should be addressed. E-mail: billiaj{at}wyeth.com.

Ror2 receptor plays a key role in bone formation, but its signaling pathway is not completely understood. We demonstrate that Ror2 homo-dimerizes at the cell surface, and that dimerization can be induced by a bivalent antibody. Antibody-mediated dimerization causes receptor autophosphorylation and induces functional consequences of its signaling, including osteogenesis in mesenchymal stem cells (MSC) and bone formation in organ culture. We further show that Ror2 associates with and phosphorylates 14–3-3{beta} scaffold protein. Endogenous Ror2 binds 14–3-3{beta} in U2OS osteosarcoma cells, and purified intracellular domain of Ror2 interacts with 14–3-3{beta} in vitro. 14–3-3{beta} is tyrosine phosphorylated in U2OS cells, and this phosphorylation is inhibited by down-regulating Ror2 and enhanced by over-expressing the kinase. Purified Ror2 phosphorylates 14–3-3{beta} in vitro, confirming 14–3-3{beta} as the first identified Ror2 substrate. Down-regulating 14–3-3{beta} potentiates osteoblastogenesis in MSC and increases bone formation in calvarial cultures, indicating that 14–3-3{beta} exerts a negative effect on osteogenesis. This raises a possibility that Ror2 induces osteogenic differentiation at least in part through a release of the 14–3-3{beta}-mediated inhibition. Our research forms a foundation for several new areas of investigation, including the molecular regulation of 14–3-3 by tyrosine phosphorylation and the role of this scaffold in osteogenesis.


Key words: Ror2 • 14–3-3{beta} • tyrosine phosphorylation • receptor tyrosine kinase • receptor dimerization







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society